WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has issued General Correspondence Letters to two third-party testing companies in China after uncovering falsified or otherwise invalid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback